BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 16183279)

  • 1. Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1.
    Liu H; Tully DC; Epple R; Bursulaya B; Li J; Harris JL; Williams JA; Russo R; Tumanut C; Roberts MJ; Alper PB; He Y; Karanewsky DS
    Bioorg Med Chem Lett; 2005 Nov; 15(22):4979-84. PubMed ID: 16183279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
    Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
    Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
    J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers.
    Tully DC; Liu H; Chatterjee AK; Alper PB; Epple R; Williams JA; Roberts MJ; Woodmansee DH; Masick BT; Tumanut C; Li J; Spraggon G; Hornsby M; Chang J; Tuntland T; Hollenbeck T; Gordon P; Harris JL; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5112-7. PubMed ID: 16876402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 3: heterocyclic P3.
    Tully DC; Liu H; Alper PB; Chatterjee AK; Epple R; Roberts MJ; Williams JA; Nguyen KT; Woodmansee DH; Tumanut C; Li J; Spraggon G; Chang J; Tuntland T; Harris JL; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1975-80. PubMed ID: 16446091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S.
    Chatterjee AK; Liu H; Tully DC; Guo J; Epple R; Russo R; Williams J; Roberts M; Tuntland T; Chang J; Gordon P; Hollenbeck T; Tumanut C; Li J; Harris JL
    Bioorg Med Chem Lett; 2007 May; 17(10):2899-903. PubMed ID: 17382545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents.
    Altmann E; Green J; Tintelnot-Blomley M
    Bioorg Med Chem Lett; 2003 Jun; 13(12):1997-2001. PubMed ID: 12781182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of alpha-ketoamides as cathepsin S inhibitors with potential applications against tumor invasion and angiogenesis.
    Chen JC; Uang BJ; Lyu PC; Chang JY; Liu KJ; Kuo CC; Hsieh HP; Wang HC; Cheng CS; Chang YH; Chang MD; Chang WS; Lin CC
    J Med Chem; 2010 Jun; 53(11):4545-9. PubMed ID: 20481438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
    J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: effect of sulfonamides P3 substituents on potency and selectivity.
    Ayesa S; Lindquist C; Agback T; Benkestock K; Classon B; Henderson I; Hewitt E; Jansson K; Kallin A; Sheppard D; Samuelsson B
    Bioorg Med Chem; 2009 Feb; 17(3):1307-24. PubMed ID: 19124252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.
    Palmer JT; Hirschbein BL; Cheung H; McCarter J; Janc JW; Yu ZW; Wesolowski G
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2909-14. PubMed ID: 16546382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azepanone-based inhibitors of human cathepsin S: optimization of selectivity via the P2 substituent.
    Kerns JK; Nie H; Bondinell W; Widdowson KL; Yamashita DS; Rahman A; Podolin PL; Carpenter DC; Jin Q; Riflade B; Dong X; Nevins N; Keller PM; Mitchell L; Tomaszek T
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4409-15. PubMed ID: 21733692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin s using the substrate activity screening method.
    Patterson AW; Wood WJ; Hornsby M; Lesley S; Spraggon G; Ellman JA
    J Med Chem; 2006 Oct; 49(21):6298-307. PubMed ID: 17034136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K.
    Black WC; Bayly CI; Davis DE; Desmarais S; Falgueyret JP; Léger S; Li CS; Massé F; McKay DJ; Palmer JT; Percival MD; Robichaud J; Tsou N; Zamboni R
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4741-4. PubMed ID: 16154747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.
    Tavares FX; Deaton DN; Miller AB; Miller LR; Wright LL; Zhou HQ
    J Med Chem; 2004 Oct; 47(21):5049-56. PubMed ID: 15456248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.
    Barrett DG; Catalano JG; Deaton DN; Hassell AM; Long ST; Miller AB; Miller LR; Shewchuk LM; Wells-Knecht KJ; Willard DH; Wright LL
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4897-902. PubMed ID: 15341947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors.
    Tully DC; Liu H; Chatterjee AK; Alper PB; Williams JA; Roberts MJ; Mutnick D; Woodmansee DH; Hollenbeck T; Gordon P; Chang J; Tuntland T; Tumanut C; Li J; Harris JL; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5107-11. PubMed ID: 16876407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors.
    Altmann E; Renaud J; Green J; Farley D; Cutting B; Jahnke W
    J Med Chem; 2002 Jun; 45(12):2352-4. PubMed ID: 12036343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.
    Crane SN; Black WC; Palmer JT; Davis DE; Setti E; Robichaud J; Paquet J; Oballa RM; Bayly CI; McKay DJ; Somoza JR; Chauret N; Seto C; Scheigetz J; Wesolowski G; Massé F; Desmarais S; Ouellet M
    J Med Chem; 2006 Feb; 49(3):1066-79. PubMed ID: 16451072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring inhibitor binding at the S' subsites of cathepsin L.
    Chowdhury SF; Joseph L; Kumar S; Tulsidas SR; Bhat S; Ziomek E; Ménard R; Sivaraman J; Purisima EO
    J Med Chem; 2008 Mar; 51(5):1361-8. PubMed ID: 18278855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.